NCT07849244

Brief Summary

The purpose of this study is to determine the clinical efficacy of The Trellis SI Joint Fusion System in unilateral sacroiliac (SI) joint fusion surgeries.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
24mo left

Started Sep 2026

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress1%
Sep 2026Sep 2028

First Submitted

Initial submission to the registry

September 8, 2026

Completed
22 days until next milestone

First Posted

Study publicly available on registry

September 30, 2026

Completed
Same day until next milestone

Study Start

First participant enrolled

September 30, 2026

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2028

Last Updated

September 30, 2026

Status Verified

September 1, 2026

Enrollment Period

1 year

First QC Date

September 8, 2026

Last Update Submit

September 28, 2026

Conditions

Keywords

degenerative sacroiliitissacroiliac disruption

Outcome Measures

Primary Outcomes (2)

  • Fusion Evaluation through Computed Tomography (CT) Scan

    Fusion evaluation through computed tomography (CT) scan at 18-month post operatively. Device placement will be confirmed by an Independent Radiologist using radiographic endpoints of the proportion of subjects who show at least 30% apposition of bone to both the iliac and sacral sides of at least 1 implant(s).

    18 months

  • Bridging Bone

    Bridging bone across the sacroiliac joint will be assessed as continuous bridging across the treated joint, occurring either adjacent to implants, distant from implants and/or adjacent/ distant from implants, degree of bridging (\<5% of joint, 5-15%, 15-30%, or 30-100%), signs of both positive and/ or adverse bone remodeling.

    18 months

Interventions

TRELLIS SI Joint Fusion System

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Primary care clinic

You may qualify if:

  • Age ≥ 21 at time of screening;
  • Diagnosis of unilateral sacroiliac (SI) joint dysfunction (degenerative sacroiliitis or sacroiliac disruption)
  • Presence of low back/buttock pain and unresponsive to non-operative treatment for at least 6 months or has the presence of progressive symptoms in the face of conservative treatment; Oswestry Disability Index (ODI) score ≥ 30%;
  • SIJ pain score ≥ 5 on 0-10 numerical rating scale (NRS);
  • Ability and willingness to comply with follow-up regimen; and
  • Written informed consent by the patient

You may not qualify if:

  • Low back/buttock pain due to other causes including, but not limited to, lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degermation, or lumbar vertebral body fracture;
  • Planned bilateral SI joint fixation
  • Received prior SI joint fusion1;
  • Cluneal neuralgia;
  • Inflammatory sacroiliitis (e.g., ankylosing spondylitis, psoriatic arthritis, reactive arthritis, non-radiographical axial spondyloarthritis, inflammatory bowel disease-associated arthritis);
  • Sacroiliac tumor as source of symptoms;
  • Sacroiliac fracture or unresolved trauma as source of symptoms;
  • Anatomic anomalies/defects that in the opinion of the Investigator preclude device placement
  • History of recent (\<1 year) major trauma to pelvis;
  • History of suspected history of severe osteoporosis (defined with a prior T-score \< -2.5 or history of osteoporotic fracture);
  • Autoimmune disorders that impact the musculoskeletal system (e.g., lupus, rheumatoid arthritis);
  • History of fibromyalgia;
  • Infection at the site of surgery;
  • Known or suspected allergies to titanium or titanium alloys
  • Pregnant (verified in patients of childbearing potential by a negative urine pregnancy test when preadmission testing is obtained), or interested in becoming pregnant during the duration of the study;
  • +7 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Northwest Specialty Hospital

Post Falls, Idaho, 83854, United States

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 8, 2026

First Posted

September 30, 2026

Study Start

September 30, 2026

Primary Completion (Estimated)

September 30, 2027

Study Completion (Estimated)

September 30, 2028

Last Updated

September 30, 2026

Record last verified: 2026-09

Data Sharing

IPD Sharing
Will not share

IPD will not be shared

Locations